Mallinckrodt achieved target enrollment of 300 participants for a phase 3 clinical study designed to evaluate the safety and efficacy of terlipressin for patients with hepatorenal syndrome type 1, according to a press release.
“Currently, there are no treatments approved in the U.S. and Canada for the treatment of [hepatorenal syndrome type 1 (HRS-1)], which is a serious disease that has a high mortality rate,” Arun Sanyal, MD, lead investigator from the Virginia Commonwealth University, said in the release. “Reaching this critical milestone of full enrollment in the CONFIRM

Source link